Pitfalls of Intranasal Naloxone

References

• Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–9.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. CDC grand rounds: prescription drug overdoses –a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3.
   PubMedGoogle Scholar
• McDonald DC, Carlson K, Izrael D. Geographic variation in opioid prescribing in the U.S. J Pain. 2012;13(10):988–96.
   PubMed Web of Science ®Google Scholar
• Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–21.
   PubMed Web of Science ®Google Scholar
• Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction. 2005;100(12):1823–31.
   PubMed Web of Science ®Google Scholar
• Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med. 2007; 49(2):172–7.
   PubMed Web of Science ®Google Scholar
• Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009; 13(4):512–5.
   PubMed Web of Science ®Google Scholar
• Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, Dunn W, Benson J, Bailey J. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29(3): 265–71.
   PubMed Web of Science ®Google Scholar
• Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Helm S, 2nd, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Emergency department visits involving nonmedical use of selected prescription drugs –United States, 2004–2008. MMWR Morb Mortal Wkly Rep. 2010;59(23):705–9.
   PubMedGoogle Scholar
• Administration SAaMHS. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11–4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
   Google Scholar
• Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One. 2013;8(4):e60600.
   PubMed Web of Science ®Google Scholar
• Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EA. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003;26(13):951–73.
   PubMed Web of Science ®Google Scholar
• Thomas S, Winecker R, Pestaner JP. Unusual fentanyl patch administration. Am J Forensic Med Pathol. 2008;29(2):162–3.
   PubMedGoogle Scholar
• Mrvos R, Feuchter AC, Katz KD, Duback-Morris LF, Brooks DE, Krenzelok EP. Whole fentanyl patch ingestion: a multi-center case series. J Emerg Med. 2012;42(5):549–52.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C. Prescription Painkiller Overdoses in the US. Vital Signs; 2011.
   Google Scholar
• Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.
   PubMed Web of Science ®Google Scholar
• Worthington N, Markham Piper T, Galea S, Rosenthal D. Opiate users’ knowledge about overdose prevention and naloxone in New York City: a focus group study. Harm Reduct J. 2006;3: 19.
   PubMedGoogle Scholar
• Stoove MA, Dietze PM, Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev. 2009;28(4):347–52.
   PubMed Web of Science ®Google Scholar
• Castillo T. Saving Lives with Narcan: Stories from the Field. Huffington Post; 2013.
   Google Scholar
• Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322(7291):895–6.
   PubMed Web of Science ®Google Scholar
• Wampler DA, Molina DK, McManus J, Laws P, Manifold CA. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care. 2011;15(3):320–4.
   PubMed Web of Science ®Google Scholar
• Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med. 2003;10(8): 893–6.
   PubMed Web of Science ®Google Scholar
• Woody GE, Metzger DS. Causes of death in injection-drug users. N Engl J Med. 1993;329(22):1661.
   PubMedGoogle Scholar
• Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med. 2007;14(7):616–23.
   PubMed Web of Science ®Google Scholar
• Kerr D, Dietze P, Kelly AM. Intranasal naloxone for the treatment of suspected heroin overdose. Addiction. 2008;103(3):379–86.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Acetyl fentanyl overdose fatalities –Rhode Island, March–May 2013. MMWR Morb Mortal Wkly Rep. 2013;62(34):703–4.
   PubMedGoogle Scholar